![Hidehito Horinouchi summarizes some abstracts of WCLC24 part 2](https://oncodaily.com/pub/uploads/2023/09/download-12-e1717230495164.jpg)
Hidehito Horinouchi summarizes some abstracts of WCLC24 part 2
Hidehito Horinouchi shared on X:
“Trailblazing Targets: New Insights
Chairs: Drs. Jacob Sands and Lorenza Landi.
HRQoL Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12
The New Generation of Cytotoxics
Chairs: Dr. Kirsty Wai-Chung Lee, Aakash Desai, Jhanelle Gray
Sacituzumab Govitecan + Pembrolizumab + Carboplatin in 1L Metastatic NSCLC: The EVOKE-02 Study
Novel Immunotherapy Strategies and Combinations
Chairs: Cheryl Ho, Anil Tibdewal
Speaker: Thomas Wu
SAFFRON-301: Tislelizumab + Sitravatinib in NSCLC Progressing on/after Chemo and Anti-PD-(L)1
Local Consolidative Therapy for Metastatic NSCLC
Chairs: Drs. John Cho and Delphine Antoni
Speaker: Dr. Shuanghu Yuan
Radiotherapy Combined with Enhanced Immunotherapy for NSCLC.”
Hidehito Horinouchi is the Assistant Chief of the National Cancer Center Hospital. He also serves as the Secretary General of the Lung Cancer Study Group, Japan Clinical Oncology Group, and the Deputy Chief of the Center for Education and Professional Career Development at the National Cancer Center Hospital. He specializes in multimodal treatment strategies, including medical, surgical, and radiation oncology, for patients with thoracic malignancies.